7. ShangPharma ( SHP) is a leading Chinese contract research organization (CRO) for the pharmaceutical and biotechnology industry. The company offers a broad range of integrated services for the discovery and development of drug candidates. ShangPharma will release its 2010 fourth quarter results on Mar. 15.

The company expects year-over-year revenue growth of 26% to 33% for the fourth quarter. For full-year 2010, net revenue is seen in the range of $89.6 to $91.1 million, representing a growth of 24% to 26%. Meanwhile, GAAP gross profit is likely to increase by 24% to 28% to $29.6 to $30.5 million. Gross margins are expected to improve on favorable service mix, effective cost control, proficient material usage, and operational efficiency.

All the five analysts covering the stock recommend a buy. Analysts polled by Bloomberg expect the stock to gain an average 32% to $16.3 from current levels over the next 12 months.

If you liked this article you might like

European Stocks Rise As Geopolitics Fall Away And Airlines Soar

London Gets BoE Boost but Earnings Weigh Elsewhere

Shire Surges on Baxalta Synergies and Strong Earnings Momentum

Handful of Earnings Drive European Stocks Higher

Europe Stocks Slip as Economic Data and Politics Return to the Fore